日报更新时间：
周报更新时间：04-18 04:06
今开价：18.84
最高价：19.28
成交量：381930.0
昨收价：18.8
最低价：18.63
最新价：18.892
英文名称：Zogenix
行业：医疗
简介：Zogenix, Inc.是一家致力于开发和商业化中枢神经系统的制药公司，或中枢神经系统，以解决那些生活孤儿，需要创新的治疗方案等中枢神经系统疾病的具体临床治疗，以帮助他们提高日常运作
电话：1-510-5508300
Zogenix, Inc.于2006年5月11日由Roger L. Hawley、Stephen J. Farr、Cam L. Garner、Jonathan M. Rigby、Bret E. Megargel及John J. Turanin创立，是一家制药公司，从事商业化与开发产品，为治疗中枢神经系统疾病与疼痛的新型药物传送平台。Zogenix公司产品组合包括Sumavel DosePro(舒马曲坦注射液)、Zohydro及Relday。 Sumavel DosePro产品：提供速效、易用于sumatriptan皮下注射，用于偏头痛与丛集型偏头痛的急性治疗。 Zohydro产品：是12小时氢可酮不含乙酰氨基酚的缓释处方，用于治疗中重度慢性疼痛的药物，需要日夜不停地鸦片疗法。 Relday产品：是专属的、长效的利培酮注射剂，合并DosePro免针头皮下注射药物系统的DURECT之SABER药物控制处方技术。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-07-02 | Farr (Stephen J) | Chief Executive Officer | Buy | 9375 | 32.00 |
| 2019-07-02 | Farr (Stephen J) | Chief Executive Officer | Sell | 19872 | 48.16 |
| 2019-07-02 | Farr (Stephen J) | Chief Executive Officer | Buy | 24063 | 10.20 |
| 2019-07-02 | Farr (Stephen J) | Chief Executive Officer | Sell | 14353 | 47.80 |
| 2019-07-02 | Farr (Stephen J) | Chief Executive Officer | Buy | 787 | 10.35 |
| 2019-07-01 | Sagrolikar (Ashish M) | Officer | Sell | 1114 | 48.72 |
| 2019-07-01 | Sagrolikar (Ashish M) | Officer | Buy | 3750 | -- |
| 2019-06-26 | Smith (Michael P) | Chief Financial Officer | Sell | 15000 | 46.32 |
| 2019-06-26 | Smith (Michael P) | Chief Financial Officer | Buy | 15000 | 10.35 |
| 2019-03-28 | Hawley (Roger L) | Former | Buy | 15700 | 33.92 |
| 2019-03-28 | Hawley (Roger L) | Former | Sell | 15700 | 55.00 |
| 2019-03-28 | Hawley (Roger L) | Former | Buy | 5000 | 20.00 |
| 2019-03-28 | Hawley (Roger L) | Former | Sell | 5000 | 55.00 |
| 2019-03-14 | Smith (Michael P) | Chief Financial Officer | Buy | 1563 | -- |
| 2019-03-14 | Smith (Michael P) | Chief Financial Officer | Sell | 541 | 51.88 |
| 2019-03-14 | Farr (Stephen J) | Chief Executive Officer | Sell | 2479 | 52.00 |
| 2019-03-14 | Farfel Gail M | Officer | Sell | 488 | 51.88 |
| 2019-03-14 | Farfel Gail M | Officer | Buy | 1625 | -- |
| 2019-03-14 | Galer (Bradley S) | Officer | Buy | 1563 | -- |
| 2019-03-14 | Galer (Bradley S) | Officer | Sell | 429 | 51.88 |
| 2019-03-14 | Farr (Stephen J) | Chief Executive Officer | Buy | 5000 | -- |
| 2019-03-13 | Hawley (Roger L) | Director | Sell | 38789 | 52.93 |
| 2019-03-12 | Hawley (Roger L) | Director | Sell | 21211 | 53.10 |
| 2019-03-05 | Tannenbaum (Renee P) | Director | Buy | 9375 | 10.40 |
| 2019-03-05 | Tannenbaum (Renee P) | Director | Buy | 20000 | 12.75 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Federated Investors Inc | 1031377 | 2.43% | -- | -- | 2019-03-31 |
| RA Capital Management, LLC | 2382168 | 5.61% | -- | -- | 2019-03-31 |
| Fidelity Management & Research Company | 2794098 | 6.58% | 351653 | 14.40% | 2019-07-31 |
| Vanguard Group Inc | 2963385 | 6.98% | 901608 | 43.73% | 2019-03-31 |
| BlackRock Inc | 3337315 | 7.86% | -245431 | -6.85% | 2019-03-31 |
| Fidelity SelectCo, LLC | 3619684 | 8.53% | 500731 | 16.05% | 2019-07-31 |
| Perceptive Advisors LLC | 3869491 | 9.12% | 79275 | 2.09% | 2019-03-31 |
| Fidelity Management and Research Company | 4624460 | 10.89% | 476829 | 11.50% | 2019-03-31 |
| FMR Inc | 4708960 | 11.09% | 524829 | 12.54% | 2019-03-31 |
| Farallon Capital Management, L.L.C. | 2050500 | 4.83% | -- | -- | 2019-03-31 |
| BlackRock Fund Advisors | 1975065 | 4.65% | -90356 | -4.37% | 2019-07-31 |
| venBio Select Advisor LLC | 1915000 | 4.51% | -60000 | -3.04% | 2019-03-31 |
| Marshall Wace Asset Management Ltd | 1129442 | 2.66% | 995419 | 742.72% | 2019-03-31 |
| Vanguard Investments Australia Ltd | 1160420 | 2.73% | -22 | -- | 2019-07-31 |
| Millennium Management LLC | 1195635 | 2.82% | 225093 | 23.19% | 2019-03-31 |
| Great Point Partners LLC | 1199545 | 2.83% | 199545 | 19.95% | 2019-03-31 |
| Cadian Capital Management LP | 1333592 | 3.14% | -1385354 | -50.95% | 2019-03-31 |
| T. Rowe Price Associates, Inc. | 1643480 | 3.87% | 588315 | 55.76% | 2019-03-31 |
| Eventide Asset Management, LLC | 1895000 | 4.46% | 182000 | 10.62% | 2019-03-31 |
| Scopia Management Inc | 1910753 | 4.50% | -1075081 | -36.01% | 2019-03-31 |
| Bank of New York Mellon Corp | 2429394 | 5.72% | -117149 | -4.60% | 2018-12-31 |
| Mellon Investments Corporation | 1304861 | 3.07% | -45160 | -3.35% | 2018-12-31 |
| Federated Equity Mgmt Co. Of Penn | 1031377 | 2.43% | 46816 | 4.76% | 2019-04-30 |
| Cadian Capital Management, LLC | 2186183 | 5.21% | 134249 | 6.54% | 2018-09-30 |
| State Street Corporation | 1016354 | 2.42% | 198443 | 24.26% | 2018-09-30 |
| BNY Mellon Asset Management North America Corporation | 1350021 | 3.22% | 506158 | 59.98% | 2018-09-30 |
| Federated Global Inv Mgmt Corp | 984561 | 2.35% | -164439 | -14.31% | 2018-09-30 |
| BlackRock Institutional Trust Company NA | 1027556 | 2.45% | 116651 | 12.81% | 2018-06-30 |
| Eagle Asset Management, Inc. | 951361 | 2.27% | -7348 | -0.77% | 2018-09-30 |
| Boston Co Asset Management LLC | 464188 | 1.30% | 464188 | -- | 2018-06-30 |
| Northern Trust Investments N A | 469941 | 1.31% | 26205 | 5.91% | 2018-06-30 |
| Polar Capital LLP | 548319 | 1.53% | 100365 | 22.41% | 2018-06-30 |
| Franklin Advisers Inc | 798025 | 2.23% | -77400 | -8.84% | 2018-06-30 |
| State Street Corp | 817911 | 2.28% | 817911 | -- | 2018-06-30 |
| Mellon Capital Management Corporation | 843863 | 2.36% | 781912 | 1262.15% | 2018-06-30 |
| Scopia Management Inc. | 5306514 | 14.81% | 1885915 | 55.13% | 2018-08-31 |
| D. E. Shaw & Co LP | 456542 | 1.27% | 379929 | 495.91% | 2018-06-30 |
| Adage Capital Partners Gp LLC | 400000 | 1.12% | -175000 | -30.43% | 2018-06-30 |
| Dimensional Fund Advisors, Inc. | 456131 | 1.30% | -2273 | -0.50% | 2018-03-31 |
| Deutsche Bank AG | 1005641 | 2.89% | 361317 | 56.08% | 2017-12-31 |
| Goldman, Sachs & Co. | 1205545 | 3.46% | -43708 | -3.50% | 2017-12-31 |
| VHCP Management II, LLC | 854057 | 2.45% | -53000 | -5.84% | 2017-12-31 |
| Ghost Tree Capital, LLC | 600000 | 2.26% | 500000 | 500.00% | 2017-09-30 |
| Citadel Advisors Llc | 626212 | 2.36% | 626212 | -- | 2017-09-30 |
| Invesco Advisers, Inc | 326412 | 1.23% | -298896 | -47.80% | 2017-09-30 |
| J.P. Morgan Investment Management Inc | 251600 | 0.95% | -10900 | -4.15% | 2017-09-30 |
| Marshall Wace North America LP | 217288 | 0.82% | 195794 | 910.92% | 2017-09-30 |
| Ascend Capital LLC | 234268 | 0.88% | 234268 | -- | 2017-09-30 |
| Longwood Capital Partners LLC | 250000 | 0.94% | -51700 | -17.14% | 2017-09-30 |
| Baker Bros Advisors LP | 1000000 | 4.03% | -- | -- | 2016-09-30 |
| Broadfin Capital, LLC | 882312 | 3.56% | -- | -- | 2016-09-30 |
| Lombard Odier Asset Management USA Corp | 625252 | 2.52% | -26166 | -4.02% | 2016-09-30 |
| Kennedy Capital Management Inc | 480452 | 1.94% | -8128 | -1.66% | 2016-09-30 |
| Sabby Management LLC | 350313 | 1.41% | -1167887 | -76.93% | 2016-12-31 |
| Opaleye Management Inc | 220000 | 0.89% | -20000 | -8.33% | 2016-09-30 |
| Aquarius Life Sciences Ltd. | 1073443 | 4.00% | 14169448 | 0.10% | 1999-11-30 |
| Sabby Management, LLC | 1237917 | 4.00% | 16340504 | 0.10% | 1999-11-30 |
| Funds affiliated with Domain Associates, L.L.C. | 1264198 | 4.00% | 16687414 | 0.10% | 1999-11-30 |
| FMR LLC | 1386212 | 4.00% | 18297998 | 0.10% | 1999-11-30 |
| Federated Investors, Inc. | 2631000 | 4.00% | 34729200 | 0.10% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Vanguard Small Cap Value Index Fund | 334635 | 0.79% | 9551 | 2.94% | 2019-06-30 |
| Vanguard Total Stock Market Index Fund | 1150888 | 2.71% | 33 | -- | 2019-06-30 |
| Eventide Gilead Fund | 1121000 | 2.64% | 182000 | 19.38% | 2019-03-31 |
| iShares Russell 2000 ETF | 941893 | 2.22% | 13030 | 1.40% | 2019-07-30 |
| Eventide Healthcare & Life Sciences Fund | 774000 | 1.82% | -- | -- | 2019-03-31 |
| Federated Kaufmann Fund | 751395 | 1.77% | -- | -- | 2019-03-31 |
| Carillon Eagle Small Cap Growth Fund | 693531 | 1.63% | -- | -- | 2019-06-30 |
| Vanguard Extended Market Index Fund | 582861 | 1.37% | 1398 | 0.24% | 2019-06-30 |
| T. Rowe Price Health Sciences Fund | 560967 | 1.32% | -393500 | -41.23% | 2019-06-30 |
| HBM Healthcare Investments AG | 553219 | 1.30% | 40000 | 7.79% | 2019-06-30 |
| BNY Mellon Sm/Md Cp Gr Fd | 344508 | 0.81% | -- | -- | 2019-06-30 |
| iShares Russell 2000 Growth ETF | 391243 | 0.92% | 4686 | 1.21% | 2019-07-30 |
| iShares Nasdaq Biotechnology ETF | 419010 | 0.99% | 4363 | 1.05% | 2019-07-30 |
| Fidelity | 515600 | 1.21% | 158300 | 44.30% | 2019-06-30 |
| Vanguard Small Cap Index | 538328 | 1.27% | 15454 | 2.96% | 2019-06-30 |
| Fidelity Advisor | 540000 | 1.27% | 80000 | 17.39% | 2019-06-30 |
| T. Rowe Price New Horizons Fund | 398598 | 0.94% | 398598 | -- | 2019-03-31 |
| iShares US Small Cap ETF (CAD-Hedged) | 857900 | 2.02% | -1440 | -0.17% | 2019-05-30 |
| Franklin Biotechnology Discovery Fund | 429910 | 1.01% | -- | -- | 2019-04-30 |
| DWS Biotech | 437696 | 1.03% | 353235 | 418.22% | 2019-04-30 |
| Vanguard Small Cap Index Fund | 516852 | 1.22% | 516852 | -- | 2019-03-31 |
| Polar Capital Healthcare Opps Fund | 371569 | 0.88% | 40000 | 12.06% | 2019-03-31 |
| Dreyfus Opportunistic Small Cap Fund | 302803 | 0.72% | -23288 | -7.14% | 2019-02-28 |
| Strategic Advisers | 331372 | 0.78% | 25182 | 8.22% | 2018-11-30 |
| Federated Kaufmann Small Cap Fund | 212784 | 0.51% | 18784 | 9.68% | 2018-09-30 |
| Emerald Growth Fund | 229294 | 0.55% | -- | -- | 2018-09-30 |
| Vanguard Extended Market Idx Inv | 465361 | 1.30% | 10600 | 2.33% | 2018-07-31 |
| DFA US Small Cap I | 108431 | 0.30% | -6123 | -5.35% | 2018-07-31 |
| CREF Stock R1 | 126312 | 0.35% | 54520 | 75.94% | 2018-07-31 |
| Invesco Global Health Care A | 164347 | 0.46% | -72923 | -30.73% | 2018-06-30 |
| SPDR | 153648 | 0.43% | -- | -- | 2018-09-13 |
| Federated Kaufmann Small Cap A | 194000 | 0.54% | -- | -- | 2018-06-30 |
| Fidelity Spartan | 161992 | 0.45% | -- | -- | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 846628 | 2.36% | -- | -- | 2018-07-31 |
| Federated Kaufmann R | 930000 | 2.60% | -305300 | -24.71% | 2018-06-30 |
| T. Rowe Price Health Sciences | 870240 | 2.43% | 126240 | 16.97% | 2018-06-30 |
| Eagle Small Cap Growth A | 693531 | 1.94% | -- | -- | 2018-06-30 |
| iShares Nasdaq Biotechnology | 474320 | 1.32% | -903 | -0.19% | 2018-09-12 |
| Eventide Healthcare & Life Sciences A | 478000 | 1.33% | 213000 | 80.38% | 2018-06-30 |
| Dreyfus Opportunistic Small Cap | 312825 | 0.87% | -- | -- | 2018-07-31 |
| Franklin Biotechnology Discovery A | 302815 | 0.85% | -- | -- | 2018-07-31 |
| iShares Russell 2000 Growth | 298630 | 0.83% | -288 | -0.10% | 2018-09-12 |
| PowerShares DWA Healthcare Momentum ETF | 119658 | 0.32% | 5439 | 4.76% | 2018-09-06 |
| Northern Trust Russell 2000 Index Fund - DC - Non-Lending | 86267 | 0.24% | -234 | -0.27% | 2018-07-31 |
| iShares Russell 2000 Value | 83493 | 0.31% | -- | -- | 2018-07-25 |
| DFA US Micro Cap I | 94426 | 0.27% | -- | -- | 2018-05-31 |
| iShares Micro-Cap | 84349 | 0.25% | -- | -- | 2018-06-14 |
| Highland Long/Short Healthcare A | 92638 | 0.35% | 92638 | -- | 2017-09-30 |
| Pru Ret Small Cap Value/Kennedy SP | 144444 | 0.54% | -36410 | -20.13% | 2017-09-30 |
| AST Small Cap Value | 106200 | 0.31% | 6100 | 6.09% | 2017-10-31 |
| AXA 2000 Managed Volatility K | 39423 | 0.16% | -- | -- | 2016-11-30 |
| Invesco VI Global Health Care II | 95229 | 0.38% | -- | -- | 2016-12-31 |
| Bridgeway Ultra-Small Company Market | 105540 | 0.43% | 105540 | -- | 2016-09-30 |
| VP Partners Small Cap Growth 2 | 159190 | 0.64% | -- | -- | 2016-12-31 |
| Fidelity® Select Biotechnology Portfolio | 1929145 | 7.80% | -498466 | -20.50% | 2015-09-30 |
| FPIL Invesco Global Health Care | 1052807 | 0.70% | -- | -- | 2015-06-30 |
| Fidelity Advisor® Biotechnology Fund | 563216 | 2.30% | -32985 | -5.50% | 2015-09-30 |
| Invesco Global Health Care Fd | 547363 | 2.20% | 547363 | -- | 2015-09-30 |
| SSgA Russell Small/Mid Cap Index Fund Tr | 452300 | 0.30% | 226800 | 100.60% | 2015-06-30 |
| Franklin Biotechnology Discovery | 391210 | 2.00% | -67900 | -14.80% | 2015-07-31 |
| iShares Russell 2000 (AU) | 389517 | 1.80% | -492 | -0.10% | 2015-11-19 |
| Tekla Life Sciences Investors | 3800811 | 2.50% | 950000 | 33.30% | 2015-06-30 |
| Cam L. Garner | Founder of 16 different companies, including: Zogenix, Inc., Mallinckrodt Hospital Products, Inc. and Verus Pharmaceuticals, Inc. Cam L. Garner is an entrepreneur and businessperson who has been the head of 12 different companies and presently occupies the position of Chairman for Evoke Pharma, Inc. (which he founded in 2007), Executive Chairman of Kalyra Pharmaceuticals, Inc. (which he founded), Chairman at Zogenix, Inc. (which he founded in 2006) and Chairman at UCSD Moores Cancer Center. He is also on the board of Neurelis, Inc. and ALASTIN Skincare, Inc. and Managing Member at Garner Investments LLC and Advisor at Windamere Venture Partners LLC. Cam L. Garner previously occupied the position of Chairman at Verus Pharmaceuticals, Inc. (he founded the company in 2009), Chairman at DJ Pharma, Inc. (he founded the company), Chairman at Meritage Pharma, Inc. (he founded the company in 2009), Chairman & Chief Executive Officer for Dura Pharmaceuticals, Inc., Chairman for Elevation Pharmaceuticals, Inc. (he founded the company in 2009), Chairman at Xcel Pharmaceuticals, Inc. (he founded the company in 2001), Chairman for Zavante Therapeutics, Inc. (he founded the company), Chairman at Mallinckrodt Hospital Products, Inc. (he founded the company in 2009), Principal at Hybritech, Inc., Director at Somaxon Pharmaceuticals, Inc., Director at OrPro Therapeutics, Inc. and Director at Oncternal Therapeutics, Inc. He received an undergraduate degree from Virginia Wesleyan University and an MBA from Baldwin-Wallace College. |
|---|---|
| Erle T. Mast | Founder of Clovis Oncology, Inc., Erle T. Mast is on the board of Zogenix, Inc. In the past he was Chief Financial Officer, Secretary & Executive VP at Clovis Oncology, Inc., Chief Financial Officer & Executive Vice President for Pharmion Corp., Partner at Deloitte & Touche LLP, CFO-Global Biopharmaceuticals Business Unit at Elan Pharma International Ltd. and Vice President-Finance for Dura Pharmaceuticals, Inc. He received an undergraduate degree from California State University-Bakersfield. |
| Roger L. Hawley | Roger L. Hawley founded Zogenix, Inc. and Dar�0�1�0�8 Bioscience, Inc. He holds the position of Chairman for Dar�0�1�0�8 Bioscience, Inc. and Chairman of Dar�0�1�0�8 Bioscience Operations, Inc. (a subsidiary of Dar�0�1�0�8 Bioscience, Inc.). Mr. Hawley is also on the board of Zogenix, Inc. (former Director, Chief Executive & Commercial Officer). In his past career he occupied the position of Vice President-Sales-CNS & GI Division at GlaxoSmithKline Plc, EVP-Commercial & Technical Operations at InterMune, Inc., Chief Commercial Officer at Prometheus Laboratories, Inc., General Manager, Vice President-Sales & Marketing at Elan Pharmaceuticals, Inc. and General Manager, Vice President-Sales & Marketing at Elan Corp. Plc. He received an undergraduate degree from Eastern Illinois University. |
| Mark C. Wiggins | Mark C. Wiggins is on the board of Zogenix, Inc. and Selection, Inc. and Chief Business Officer for TRACON Pharmaceuticals, Inc. In the past Mr. Wiggins occupied the position of Executive VP-Corporate & Business Development at Biogen, Inc. Executive Vice President for Biogen Idec New Ventures, Inc. and EVP-Corporate & Business Development at IDEC Pharmaceuticals Corp. (both are subsidiaries of Biogen, Inc.), Senior VP-Corporate & Business Development at Elcelyx Therapeutics, Inc., Vice President-Marketing at Idera Pharmaceuticals, Inc., Director-Business Development for Schering-Plough Corp., Principal at Johnson & Johnson Innovation JJDC, Inc., Chief Business Officer of Mpex Pharmaceuticals, Inc. and Marketing Director at Schering Corp. Mark C. Wiggins received an undergraduate degree from Syracuse University and an MBA from the University of Arizona. |
| Michael Patrick Smith | Currently, Michael Patrick Smith holds the position of CFO, Secretary, Treasurer & Executive VP at Zogenix, Inc. He is also on the board of Zogenix International Ltd. and Zogenix Europe Ltd. In the past he occupied the position of Manager-Business Development & Finance at Ascent Logic Corp., Chief Financial Officer, Secretary & Treasurer of Horizon Pharmaceutical LLC, CFO & Head-Business Development at Memory Pharmaceuticals Corp., Chief Financial Officer at Raptor Pharmaceuticals, Inc., Vice President-Business Development for iPierian, Inc., Senior Associate at Watson Wyatt Worldwide, Inc., Vice President-Business Development at QLT, Inc. and Director-Corporate Development at Chiron Corp. He received an undergraduate degree from the University of Virginia and an MBA from Haas School of Business. |
| Louis C. Bock | Mr. Lou C. Bock is Independent Director at Heat Biologics, Inc., Independent Director at Zogenix, Inc., Independent Director at Orexigen Therapeutics, Inc., and Venture Partner at Sant�0�1�0�8 Health Ventures LLC. He is on the Board of Directors at Ascenta Therapeutics, Inc., Sonexa Therapeutics, Inc., Arizona Science & Technology Enterprises LLC, New Century Hospice, Inc., PowerVision, Inc., Molecular Templates, Inc., and CardioKinetix, Inc. Prior to joining Sant�0�1�0�8 in 2014, Mr. Bock was a Partner and Co-Founder of Scale Venture Partners from 1997-2014. He was a member of the healthcare team and built the firm's biotech practice. He joined Scale in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. Prior to Gilead, he was a research associate at Genentech. He was previously employed as a Independent Director by Horizon Pharma, Inc. He also served on the board at diaDexus, Inc., VaxGen, Inc., Horizon Pharma USA, Inc., SGX Pharmaceuticals, Inc., diaDexus, Inc., Dynavax Technologies Corp., Cellective Therapeutics, Inc., Horizon Therapeutics, Inc., Prestwick Pharmaceuticals, Inc., and Somaxon Pharmaceuticals, Inc. Mr. Bock holds an M.B.A. in Finance from California State University, San Francisco and a B.S. in Biology from California State University, Chico. |
| Stephen James Farr | Stephen James Farr founded Zogenix, Inc. Presently, Dr. Farr is President, Chief Executive Officer & Director at this company. He is also Member of Royal Pharmaceutical Society of Great Britain and on the board of 7 other companies. In his past career he held the position of Scientific Director at Novo Nordisk A, Chief Scientific Officer & Senior Vice President at Aradigm Corp. and Professor at Welsh School of Pharmacy. Stephen James Farr received a doctorate from The University of Wales and an undergraduate degree from De Montfort University. |
| James B. Breitmeyer | Founder of Zogenix, Inc., James B. Breitmeyer is an American businessperson who has been at the head of 5 different companies and currently is President, Chief Executive Officer & Director at Oncternal Therapeutics, Inc. Dr. Breitmeyer is also on the board of Zogenix, Inc. and Otonomy, Inc. In the past Dr. Breitmeyer held the position of Chief Medical Officer & Senior Vice President for Serono International SA, Chief Development Officer & Executive VP at Bavarian Nordic An and President of Bavarian Nordic, Inc. (a subsidiary of Bavarian Nordic A), President, Chief Executive Officer & Director at Tokalas, Inc., President, Chief Executive Officer & Director at Oncternal Oncology, Inc., Chief Medical Officer & Senior Vice President for Merck Serono SA, Chief Medical Officer at EMD Serono, Inc., Chief Medical Officer & Executive VP-Development at Mallinckrodt Hospital Products, Inc., Chief Medical Officer & Vice President at Applied Molecular Evolution, Inc. and President & Chief Executive Officer for The Baim Institute for Clinical Research. James B. Breitmeyer received a doctorate from Washington University School of Medicine and an undergraduate degree from the University of California, Santa Cruz. |
| Gail M. Farfel | Dr. Thierry Darcis is Executive VP & General Manager-Europe Region at Zogenix, Inc. He is on the Board of Directors at Zogenix International Ltd. Dr. Darcis was previously employed as General Manager by Shire ViroPharma, Inc. He received his undergraduate degree from Solvay Business School of Economics & Management, an MBA from the University of Stellenbosch and a doctorate degree from Universit�0�1�0�8 Catholique de Louvain. |
| Renee P. Tannenbaum | Renee P. Tannenbaum is on the board of Zogenix, Inc. and Vice President-Global Alliances at Halozyme, Inc. In her past career Dr. Tannenbaum was President for Myrtle Potter & Co. LLC, Head-Global Customer Excellence at AbbVie, Inc., Chief Commercial Officer & Executive VP at Elan Pharmaceuticals, Inc. and Professor at the University of the Sciences in Philadelphia. She received an undergraduate degree and a doctorate from the University of Connecticut, an MBA from Temple University (Pennsylvania) and a doctorate from Philadelphia College of Pharmacy. |
| Edward F. Smith | Dr. Edward F. Smith is a SVP-Regulatory Affairs & Quality Assurance at Conatus Pharmaceuticals, Inc. and a Vice President-Regulatory Affairs & Drug Safety at Zogenix, Inc. Dr. Smith was previously employed as a Senior Director-Regulatory Affairs by Connetics Corp., a Senior Director-Regulatory Affairs by Stiefel Research Institute, Inc., a Director-Regulatory Affairs by Nektar Therapeutics, a Principal by Valeant Pharmaceuticals International Corp., a Principal by Radiance Medical Systems, Inc., a Principal by Mallinckrodt, Inc., a Principal by Eskayef Ltd., a Principal by Bank of America Corp., and an Independent Director by Residential Capital LLC. He received his undergraduate degree from Brown University, an undergraduate degree from Montana State University, an MBA from Harvard University, an MBA from the University of Washington and a doctorate degree from Thomas Jefferson University. |
| Erle T. Mast | Founder of Clovis Oncology, Inc., Erle T. Mast is on the board of Zogenix, Inc. In the past he was Chief Financial Officer, Secretary & Executive VP at Clovis Oncology, Inc., Chief Financial Officer & Executive Vice President for Pharmion Corp., Partner at Deloitte & Touche LLP, CFO-Global Biopharmaceuticals Business Unit at Elan Pharma International Ltd. and Vice President-Finance for Dura Pharmaceuticals, Inc. He received an undergraduate degree from California State University-Bakersfield. |
| Bradley S. Galer | Presently, Bradley S. Galer holds the position of Chief Medical Officer & Executive Vice President at Zogenix, Inc. He is also on the board of Zogenix International Ltd. In the past he held the position of President-Pain Group at Nuvo Pharmaceuticals, Inc. and Senior Medical Officer & VP-Scientific Affairs at Endo Pharmaceuticals, Inc. He received a doctorate from Albert Einstein College of Medicine, Inc. |
| Arnold R. Gammaitoni | Presently, Arnold R. Gammaitoni is Vice President-Medical & Scientific Affairs at Zogenix, Inc. Dr. Gammaitoni previously was Vice President-Scientific Affairs at Nuvo Pharmaceuticals, Inc. Dr. Gammaitoni received a doctorate from the University of the Sciences in Philadelphia. |
| Jeff D. Durflinger | Jeff D. Durflinger is VP-Technical Operations & Product Supply at Zogenix, Inc. Mr. Durflinger received a graduate degree from Golden Gate University and an undergraduate degree from California State University-Chico. |
| Gail M. Farfel | Gail M. Farfel is on the board of DURECT Corp., Zogenix International Ltd., PrintedArt and American Society For Experimental Neurotherapeutics and Chief Development Officer & Executive VP at Zogenix, Inc. In the past Dr. Farfel held the position of President for G Meredith Consulting LLC, Chief Clinical & Regulatory Officer at Marinus Pharmaceuticals, Inc., Senior Associate Director at Pfizer Inc. and Global Team Lead at Pfizer Pharmaceuticals, Inc. (a subsidiary of Pfizer Inc.) and Vice President-Therapeutic Area at Novartis Pharmaceuticals Corp. Dr. Farfel received a doctorate from The University of Chicago and an undergraduate degree from the University of Virginia. |
| Catherine O'Connor | Catherine O'Connor is Senior Director-Commercial Communications at Zogenix, Inc. |
| Steven A. Johnson | Currently, Steven A. Johnson occupies the position of Vice President, Legal Council & Compliance Office at Zogenix, Inc. He received an undergraduate degree from Boston College and a graduate degree from Suffolk University. |
| Ashish Sagrolikar | Ashish Sagrolikar is Chief Commercial Officer & Executive VP of Zogenix, Inc. Mr. Sagrolikar previously occupied the position of VP-US Hemophilia Franchise at Baxter International, Inc. and Vice President-Business Development of Baxter BioScience Corp. (a subsidiary of Baxter International, Inc.) and VP-Immunology Marketing & Rare Disease at GlaxoSmithKline LLC. He received an MBA from International Institute for Management Development and an undergraduate degree from Government College of Pharmacy Karad. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 0
暂无评论